IBJNews

Chao exit hurts drug development industry

Back to TopCommentsE-mailPrintBookmark and Share

Purdue University’s decision to close the Chao Center in West Lafayette is a setback for Indiana’s effort to grow a vibrant contract drug manufacturing sector. But it’s just the latest in a series of unexpected changes—not all for the worse—since Indianapolis-based BioCrossroads launched a contract drug manufacturing initiative in late 2007.

The Chao Center formulated and manufactured small batches of chemical drugs used in clinical trials and performed analysis on experimental drugs. Purdue is hoping to find a private company to come in and take over the 5-year-old facility.

“That is a loss for our system,” said BioCrossroads CEO David Johnson. “It’s more a loss for the scientific part of our system than the business part.”

What BioCrossroads hoped to do was to package and pitch a full range of services offered by Indiana companies to help small drug-discovery firms move their experimental compounds through the various stages of testing. BioCrossroads still maintains an office in one of the nation's hotspots for drug discovery, San Diego.

But since that office opened in early 2008, the entire industry has changed. When the stock market melted down in late 2008, venture capital dried up for drug- discovery firms, pushing them to seek out large pharmaceutical companies to help develop their drugs.

As such deals were struck, large drug companies, such as Indianapolis-based Eli Lilly and Co., were also looking to outsource more work to contract research and manufacturing firms as a way to reduce their costs.

“The contract drug development is brisker than ever, but you’ve got to pay attention to who’s paying the bills,” Johnson said. More often, big pharma is writing the checks, he said, even if a drug being developed is owned by a small biotech firm.

The recession prevented the Chao Center for Industrial Pharmacy and Contract Manufacturing from getting enough business to make a profit, according to Joe Hornett, director of the Purdue Research Park. The Chao Center’s most consistent work was making seromycin, a medicine to treat drug-resistant tuberculosis, for Lilly.

It’s not clear how much interest the Chao Center might generate among private contract-manufacturing firms. Lilly successfully sold its manufacturing facility in Lafayette to Germany-based Evonik AG last year, after shopping it for a year, by promising to be the facility’s first customer.

Johnson said Purdue could also package itself and its scientists as it pitches the Chao Center to private firms. “The attraction for an outside party would obviously be the relationship with Purdue,” he said.

ADVERTISEMENT

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. By Mr. Lee's own admission, he basically ran pro-bono ads on the billboard. Paying advertisers didn't want ads on a controversial, ugly billboard that turned off customers. At least one of Mr. Lee's free advertisers dropped out early because they found that Mr. Lee's advertising was having negative impact. So Mr. Lee is disingenous to say the city now owes him for lost revenue. Mr. Lee quickly realized his monstrosity had a dim future and is trying to get the city to bail him out. And that's why the billboard came down so quickly.

  2. Merchants Square is back. The small strip center to the south of 116th is 100% leased, McAlister’s is doing well in the outlot building. The former O’Charleys is leased but is going through permitting with the State and the town of Carmel. Mac Grill is closing all of their Indy locations (not just Merchants) and this will allow for a new restaurant concept to backfill both of their locations. As for the north side of 116th a new dinner movie theater and brewery is under construction to fill most of the vacancy left by Hobby Lobby and Old Navy.

  3. Yes it does have an ethics commission which enforce the law which prohibits 12 specific items. google it

  4. Thanks for reading and replying. If you want to see the differentiation for research, speaking and consulting, check out the spreadsheet I linked to at the bottom of the post; it is broken out exactly that way. I can only include so much detail in a blog post before it becomes something other than a blog post.

  5. 1. There is no allegation of corruption, Marty, to imply otherwise if false. 2. Is the "State Rule" a law? I suspect not. 3. Is Mr. Woodruff obligated via an employment agreement (contractual obligation) to not work with the engineering firm? 4. In many states a right to earn a living will trump non-competes and other contractual obligations, does Mr. Woodruff's personal right to earn a living trump any contractual obligations that might or might not be out there. 5. Lawyers in state government routinely go work for law firms they were formally working with in their regulatory actions. You can see a steady stream to firms like B&D from state government. It would be interesting for IBJ to do a review of current lawyers and find out how their past decisions affected the law firms clients. Since there is a buffer between regulated company and the regulator working for a law firm technically is not in violation of ethics but you have to wonder if decisions were made in favor of certain firms and quid pro quo jobs resulted. Start with the DOI in this review. Very interesting.

ADVERTISEMENT